Hypothesis

Chronic SASP drives a maladaptive reprogramming of tissue-resident macrophages that impairs their ability to clear senescent cells, thereby creating a self-reinforcing loop of senescence accumulation. We hypothesize that interleukin-6 (IL-6) trans-signaling, a prominent SASP component, activates STAT3 in macrophages, leading to up-regulation of SOCS3 and down-regulation of phagocytic receptors such as MerTK and AXL. This renders macrophages refractory to the "eat-me" signals exposed by senescent cells, diminishing immune-mediated clearance even when senolytic drugs induce apoptosis. Consequently, the efficacy of senolytics is limited in tissues where macrophage-derived IL-6 trans-signaling is high.

Testable predictions

1. In aged mice, combined treatment with a senolytic (e.g., dasatinib/quercetin) and an antibody that blocks IL-6 trans-signaling (anti-IL-6R) will reduce senescent cell burden more than senolytic alone, as measured by p16^Ink4a^ positivity and SASP cytokine levels in multiple organs.
2. Macrophage-specific deletion of Stat3 will phenocopy the benefit of IL-6R blockade, enhancing senolytic-mediated clearance without altering senolytic pharmacokinetics.
3. Depletion of macrophages (using clodronate liposomes) will abolish the additive effect of IL-6R blockade, confirming that the observed synergy depends on macrophage activity.
4. In human tissue explants from older donors, exposure to recombinant IL-6/sIL-6R will decrease macrophage phagocytosis of senescent cell-derived apoptotic bodies, an effect rescued by STAT3 inhibition.

Mechanistic rationale The SASP is not merely a by-product of senescence; its cytokine milieu shapes the immune niche. While acute SASP recruits immune cells for clearance, chronic exposure skews macrophages toward an M2-like, tolerogenic state via STAT3-SOCS3 signaling, as documented in cancer-associated macrophages and fibrosis models [7]. This mirrors the observed age-related shift toward Th2 polarization and NK cell dysfunction that hampers senescent cell surveillance [7]. By blocking IL-6 trans-signaling, we restore macrophage competence to recognize and engulf apoptotic senescent cells, thereby breaking the feedback loop that sustains senescence accumulation.

Falsifiability If combined senolytic + IL-6R blockade fails to improve clearance over senolytic alone, or if macrophage Stat3 deletion does not enhance senolytic efficacy, the hypothesis would be refuted. Similarly, if IL-6 trans-signaling inhibition does not alter macrophage phagocytic markers or if macrophage depletion does not remove the synergistic effect, the proposed mechanism would be invalid.

References

• Senolytics improve physical function and increase lifespan in old age [1]
• How the body really ages: 7 million cells mapped across 21 organs [2]
• Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker [3]
• Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis [4]
• Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration [5]
• Rejuvenation Roundup February 2026 [6]
• Senescent cell clearance by the immune system [7]
• Recent Advancement in Elimination Strategies [8]